Description
| Description | TRV-120027 acetate is a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1 receptor) and engages -arrestins while blocking G-protein signaling. |
| In vitro | TRV120027 TFA (100 nM) induces an [Ca2+]i increase in HEK293 cells co-transfected with AT1R, β-arrestin-1, and TRPC3, which are significantly blocked by Pyr3 pre-incubation in HEK293 cells co-transfected with Flag-AT1R-Cherry, HA-β-arrestin-1, and TRPC3-GFP. TRV120027 TFA (100 nM) significantly increases the AT1R and TRPC3 association with the immunoprecipitated β-arrestin-1 in HEK293 cells co-transfected with Flag-AT1R-cherry, TRPC3-GFP, and HA-β-arrestin-1 [2]. |
| In vivo | TRV120027 TFA (i.v.; 0.3 or 1.5 μg/kg per minute; infusion rate, 0.5 mL/min), when added to furosemide, decreases cardiac preload and afterload, systemic and renal vascular resistance, and left ventricular external work while increasing cardiac output and renal blood flow [1]. |
| Molecular Weight |
986.14 |
| Formula | C45H71N13O12 |
| CAS No. | TP2158L1 |
Storage
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Solubility Information
( < 1 mg/ml refers to the product slightly soluble or insoluble )
